急性护理综合症检测市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按疾病类型、目标、样本类型、最终用户、地区、竞争细分

全球急性护理综合症检测市场在2022 年达到28.9 亿美元的估值，并预计在预测期内大幅增长，预计到2028 年复合年增长率(CAGR) 为5.56%，预计2028 年将达到40 亿美元。2028. 急性护理综合症检测是医疗机构中使用的一种诊断方法，特别是在急诊科和急诊护理机构中，用于快速识别和诊断患者急性症状或病症的根本原因。这种方法涉及同时测试多种病原体，包括病毒、细菌和其他微生物，这些病原体可能导致患者的症状。目的是迅速缩小潜在原因的范围并指导适当的治疗决策。事实证明，在患者表现出由各种传染源引起的症状的情况下，急性护理综合症检测尤其有价值。它使医疗保健提供者能够就患者护理、隔离方案和治疗选择做出及时且明智的决策。这种测试方法在疾病爆发或大流行期间变得尤其重要，有助于医疗保健系统有效管理和应对大量涌入的出现类似症状的患者。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	28.9亿美元
2028 年市场规模	40亿美元
2023-2028 年复合年增长率	5.56%
成长最快的细分市场	呼吸系统疾病
最大的市场	亚太地区

1.传染病爆发的增加促进了市场成长：

传染病爆发的升级极大地推动了全球急性护理综合症检测市场的扩张。传染病的爆发对快速、准确的诊断解决方案提出了更高的需求，而急性护理综合症检测可以有效解决这个问题。这种测试方法有助于在疫情爆发期间快速识别致病病原体。快速诊断可以及早发现并及时实施遏制策略，例如隔离感染者和执行感染控制措施。急性护理综合症检测透过对导致爆发的潜在病原体进行全面分析，简化了患者管理，从而可以製定适当的护理计划和治疗。迅速辨识病原体有助于限制疫情在社区和医疗机构内的传播。急性护理综合症检测在识别携带者、隔离病例和遏制进一步传播方面发挥作用。

2. 对及时诊断的需求不断增长推动成长：

对及时诊断的日益增长的需求在推动全球急性护理综合征检测市场方面发挥关键作用。及时诊断对于各种医疗状况至关重要，特别是在急诊环境中，快速且准确的诊断可以显着影响患者的治疗结果。及时、准确的诊断对于急诊和急诊护理机构尤其重要。急性护理综合症检测可对潜在病原体进行全面评估，使医疗保健提供者能够及时查明症状原因并启动适当的治疗策略。急性护理综合症测试平台旨在快速提供结果，通常在几个小时内。在必须立即诊断以防止疾病进展和併发症的情况下，这种快速的周转时间证明是至关重要的。及时诊断可以提高医疗保健提供者管理患者病情、促进患者分诊、隔离方案和有针对性的干预措施的效率。传统的诊断方法可能会因实验室处理时间和样本运输而出现延误，而与此不同的是，急性护理综合征检测可以降低此类延误的风险，确保及时诊断和治疗。透过这种方法进行快速诊断可以改善患者的治疗效果，儘早开始适当的治疗可以降低疾病的严重程度、死亡率和併发症。

3. 越来越多采用即时侦测推动成长：

即时护理 (POC) 检测的广泛采用是全球急性护理综合症检测市场成长的重要推动力。护理点测试是指在患者所在地或附近进行的诊断测试，有助于立即得出结果，并指导快速的临床决策。急性护理综合症检测整合到 POC 平台后，可以快速识别导致急性症状的病原体，从而采取更及时、更合适的干预措施。 POC 测试无需将样品运送到集中实验室，从而缩短了结果的周转时间。在急诊环境等时间敏感性至关重要的环境中，POC 测试可加速适当治疗的启动。传统的实验室检测通常需要将样本送到中心实验室，导致等待结果的时间延长。 POC 检测消除了样本运输和处理延迟的需要，确保患者得到快速诊断。 POC 检测有助于在护理点进行全面的患者护理，最大限度地减少患者在设施内移动进行检测的必要性。事实证明，这对于行动不便的危重病患尤其有价值。 POC 测试透过减少额外测试、咨询和程序的需求来优化医疗资源分配。这可以节省成本并提高医疗保健效率。在紧急情况下，POC 测试可以快速提供关键的诊断讯息，使医疗保健提供者能够做出明智的决策并优先考虑患者护理。

主要市场挑战

1.与其他诊断测试的竞争：

综合征测试与其他诊断测试（例如分子诊断和血清学诊断）竞争。这些测试可以提供有关综合症根本原因的更准确资讯。分子诊断可以找出引起此综合症的特定病原体，而血清学诊断可以检测病原体抗体的存在。这些见解可以指导诊断和治疗决策。医疗保健提供者可能习惯于采用他们已经熟悉的传统诊断方法，这可能导致不愿意采用更新的综合征检测方法。具有悠久历史和既定可靠性的诊断方法可能会受到医疗保健专业人员的青睐，这使得综合症检测很难获得认可。

2. 品质控制和标准化：

品质控制和标准化为全球急性护理综合征检测市场带来了重大挑战。确保不同综合征检测平台和检测结果一致且准确对于诊断结果的可靠性和可重复性至关重要。综合征测试平台可能采用不同的技术、化学物质和试剂，这可能导致检测性能的变化。灵敏度、特异性和检测极限的差异会影响结果的准确性和可靠性。症状检测可以在各种实验室环境中进行，包括临床实验室、医院和护理点设施。测试程序、设备和人员专业知识的实验室间差异可能会影响结果的一致性。同时针对多种病原体的综合征检测需要最大限度地减少不同目标之间的交叉反应或干扰。交叉反应可能会产生假阳性或假阴性结果。

3. 与医疗保健系统整合：

将综合征检测技术整合到现有的医疗保健系统和工作流程中是全球急性护理综合征检测市场的一项重大挑战。无缝整合对于最大限度地发挥这些技术的优势和广泛采用至关重要。症状检测平台需要与现有的医疗资讯系统、电子健康记录（EHR）和实验室资讯管理系统（LIMS）相容。确保顺利的资料交换和互通性在技术上可能很复杂。症状测试会产生大量资料，需要相关医疗保健专业人员进行安全管理、储存和存取。建立强大的资料管理和连接解决方案至关重要。设计使用者友善的介面，使医疗保健提供者能够在现有工作流程中轻鬆存取和解释症状测试结果，这本身就面临着挑战​​。使用者介面的设计必须优先考虑可用性和效率。医疗保健人员，包括临床医生、实验室技术人员和 IT 人员，需要接受培训才能有效使用和整合综合征检测技术。培训计划必须全面且持续。引进新技术通常需要改变现有的临床和实验室工作流程。克服变革阻力并确保平稳过渡对于成功整合至关重要。

主要市场趋势

1. 即时检测 (POCT) 的兴起：

即时护理检测（POC​​T）的兴起成为全球急性护理症候群检测市场的重要趋势。现场护理测试涉及在患者所在地或附近进行的诊断测试，提供快速结果，指导立即临床决策。 POCT 使医疗保健提供者能够快速诊断并启动治疗计划，特别是在时间敏感性至关重要的急性护理环境中。急性护理综合症检测适用于 POCT 平台后，有助于及时识别导致急性症状的病原体，从而采取更及时、更合适的干预措施。在护理点进行症状检测无需将样本送到集中实验室，从而缩短了结果的周转时间。这种速度对于管理紧急情况和疫情至关重要，因此迅速做出决定至关重要。护理点综合征测试使医疗保健提供者能够在床边做出明智的决定。即时结果指导隔离措施、治疗选择和病患管理策略，共同增强整体照护。在传染病爆发等情况下，基于 POCT 的急性护理综合征检测有助于快速识别病例并实施适当的控制措施以防止进一步传播，从而有助于快速遏制。 POCT 无需不必要的转运、重复检测和延长住院时间，从而优化资源分配。这种效率在资源有限的急诊护理场景中尤其重要。面对大型集会或灾难应变等事件，即时症状检测可以快速筛检传染病，有助于快速识别和管理潜在的疫情。 POCT 在进入中心实验室的机会有限的偏远或服务欠缺地区尤其有利。护理点的急性护理综合症检测弥补了诊断差距，增强了即时疾病监测、新出现病原体的早期发现以及及时的公共卫生应对措施。

细分市场洞察

疾病类型见解

2022 年，呼吸系统疾病领域主导了急性护理综合症检测市场，预计在未来几年将继续扩张。呼吸系统疾病是全球主要死亡原因之一。根据世界卫生组织 (WHO) 统计，2019 年呼吸系统疾病导致约 410 万人死亡。呼吸系统疾病往往表现迅速，给诊断和治疗带来了挑战。症状检测对于确定这些疾病的根本原因并及时开始治疗起着至关重要的作用。鑑于呼吸道疾病通常有常见的症状，如咳嗽、发烧和呼吸急促，急性照护症候群检测有助于区分各种呼吸道病原体并指导适当的治疗策略。呼吸道疾病在公共卫生影响、快速传播和广泛后果方面的重要性凸显了透过急诊症候群检测进行有效疫情管理和遏制的重要性。预计 2023 年至 2030 年该细分市场将经历最高的复合年增长率 (CAGR)。

目标洞察

2022 年，细菌细分市场在急性护理症候群检测市场中占据主导地位，预计未来几年将保持成长动能。细菌是在单一循环中包含遗传讯息的简单细胞，它们可以引起一系列影响人类和动物的感染。细菌感染可出现在身体的各部位，包括皮肤、脑部、肺部、血液等。细菌感染通常进展迅速，为诊断和治疗带来挑战。急性护理综合症检测在确定细菌感染的根本原因、促进早期干预方面发挥关键作用。鑑于细菌感染具有传染性，及时诊断对于预防疾病传播至关重要。凭藉其快速结果，症状检测已被证明可以有效改善患者的治疗效果。

样本洞察

2022 年，拭子细分市场主导了急性护理综合症检测市场，预计未来将维持其成长轨迹。鼻咽拭子在采集上呼吸道检体特别有效，上呼吸道中常见各种呼吸道病原体，包括流感和冠状病毒等病毒。鼻咽拭子可直接进入鼻咽部，鼻咽部通常是许多呼吸道病毒的初始感染部位。这种接近性提高了病原体检测的灵敏度。

最终用户洞察

2022年，医院部门在急性护理综合症检测市场中占据显着地位，预计将继续扩大。医院是管理急性医疗状况、紧急情况和疫情的主要场所。事实证明，在这些环境中，为了及时诊断和管理有紧急医疗需求的患者，症状检测尤其不可或缺。医院容纳不同的患者群体，并且经常处理大量患者，这使得医院成为综合征检测的关键。快速识别多种病原体对于患者护理和感染控制至关重要。医院急诊室会遇到大量涌入的急性病例，而症状检测可以简化此类情况下的分流和决策，从而能够及时进行干预。

区域洞察

北美已成为全球急性护理症候群检测市场的领导者。尤其是美国和加拿大，拥有先进且发达的医疗保健基础设施，可促进创新诊断技术（包括急性护理综合症检测）的快速采用和整合。该地区是技术创新和医疗保健研究的中心，推动了尖端综合征检测平台和解决方案的开发。

请随时联繫以获取更多资讯或其他见解。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球急性照护症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型（呼吸道疾病、胃肠疾病、泌尿生殖系统疾病、热带疾病、其他）
  • 依目标（细菌、病毒、真菌、寄生虫）
  • 依样本类型（血液、尿液、生物液体、粪便、拭子、其他）
  • 按最终使用者（医院、临床和诊断实验室、研究和学术机构、其他）
  • 按公司划分 (2022)
  • 按地区
• 市场地图

第 6 章：北美急性护理症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型
  • 按目标
  • 依样品类型
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲急性护理症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型
  • 按目标
  • 依样品类型
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区急诊症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型
  • 按目标
  • 依样品类型
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲急性护理症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型
  • 按目标
  • 依样品类型
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲急性护理症候群检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依疾病类型
  • 按目标
  • 依样品类型
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非急诊护理症候群检测
  • 沙乌地阿拉伯急诊症候群检测
  • 阿联酋急性护理症候群检测

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA (BioFire Diagnostics)
  • Danaher Corporation (Cepheid, Inc.)
  • DiaSorin SpA (Luminex Corporation)
  • Eurofins Scientific (Eurofins Viracor)
  • Karius
  • Laboratory Corporation of America Holdings.
  • QIAGEN NV
  • QuantuMDx Group Ltd.

第 16 章：策略建议

The Global Acute Care Syndromic Testing Market achieved a valuation of USD 2.89 Billion in 2022 and is poised for substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.56% through 2028 and expected to reach at USD 4.00 Billion in 2028. Acute Care Syndromic Testing serves as a diagnostic approach utilized in healthcare settings, particularly in emergency departments and acute care facilities, for swiftly identifying and diagnosing the underlying causes of acute symptoms or conditions in patients. This methodology involves simultaneously testing for multiple pathogens, including viruses, bacteria, and other microorganisms, that could be responsible for a patient's symptoms. The objective is to promptly narrow down potential causes and guide appropriate treatment decisions. Acute care syndromic testing proves particularly invaluable in scenarios where patients exhibit symptoms attributable to various infectious agents. It enables healthcare providers to make timely and well-informed decisions about patient care, isolation protocols, and treatment choices. This testing approach becomes especially critical during disease outbreaks or pandemics, aiding healthcare systems in effectively managing and responding to a significant influx of patients presenting similar symptoms.

However, it is important to note that the specific types of tests used in acute care syndromic testing may encompass molecular assays (such as polymerase chain reaction or PCR tests), rapid antigen tests, serological tests (for detecting antibodies), and other diagnostic methods. The selection of tests depends on the suspected pathogens and the clinical context.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 2.89 Billion
Market Size 2028	USD 4.00 Billion
CAGR 2023-2028	5.56%
Fastest Growing Segment	Respiratory Disease
Largest Market	Asia Pacific

1. Rise in Infectious Disease Outbreaks Boosts Market Growth:

The escalation of infectious disease outbreaks significantly fuels the expansion of the global acute care syndromic testing market. Outbreaks of infectious diseases generate an elevated demand for rapid and accurate diagnostic solutions, which acute care syndromic testing effectively addresses. This testing approach facilitates the quick identification of the responsible pathogens during outbreaks. Speedy diagnosis enables early detection and the timely implementation of containment strategies, such as isolating infected individuals and enforcing infection control measures. Acute care syndromic testing streamlines patient management by offering a comprehensive analysis of potential pathogens driving an outbreak, which in turn allows for appropriate care planning and treatment. Swiftly identifying the causative agent aids in limiting the spread of the outbreak within the community and healthcare settings. Acute care syndromic testing plays a role in identifying carriers, isolating cases, and curbing further transmission.

2. Increasing Demand for Timely Diagnostics Drives Growth:

The growing need for timely diagnostics plays a pivotal role in propelling the global acute care syndromic testing market. Timely diagnostics hold vital importance across various medical conditions, particularly in acute care settings where rapid and precise diagnosis can significantly influence patient outcomes. Prompt and accurate diagnosis is especially crucial in emergency departments and acute care facilities. Acute care syndromic testing provides a comprehensive assessment of potential pathogens, enabling healthcare providers to promptly pinpoint the cause of symptoms and initiate suitable treatment strategies. Acute care syndromic testing platforms are designed to deliver swift results, often within a matter of hours. This rapid turnaround time proves vital in situations where immediate diagnosis is imperative to prevent disease progression and complications. Timely diagnostics enhance the efficiency of healthcare providers in managing patients' conditions, facilitating patient triage, isolation protocols, and targeted interventions. Unlike traditional diagnostic methods that can experience delays due to laboratory processing times and sample transportation, acute care syndromic testing mitigates the risk of such delays, ensuring timely diagnoses and treatments. Rapid diagnosis through this approach can lead to improved patient outcomes, with early initiation of appropriate therapies reducing the severity of illness, mortality rates, and complications.

3. Increased Adoption of Point-of-Care Testing Drives Growth:

The heightened adoption of point-of-care (POC) testing serves as a significant driver for the growth of the global acute care syndromic testing market. Point-of-Care Testing refers to diagnostic testing performed at or near the patient's location, facilitating immediate results that guide swift clinical decision-making. Acute care syndromic testing, when integrated into POC platforms, enables the rapid identification of pathogens responsible for acute symptoms, resulting in more timely and suitable interventions. POC testing eliminates the need to transport samples to centralized laboratories, reducing turnaround times for results. In environments like acute care settings where time sensitivity is paramount, POC testing accelerates the initiation of appropriate therapies. Traditional laboratory testing often entails sending samples to central labs, leading to extended waiting times for results. POC testing obviates the need for sample transportation and processing delays, ensuring that patients receive rapid diagnoses. POC testing facilitates comprehensive patient care at the point of care, minimizing the necessity for patients to move within a facility for testing. This proves especially valuable for critically ill patients with limited mobility. POC testing optimizes healthcare resource allocation by reducing the requirement for additional tests, consultations, and procedures. This can yield cost savings and enhance healthcare efficiency. During emergencies, POC testing offers crucial diagnostic information rapidly, empowering healthcare providers to make informed decisions and prioritize patient care.

Key Market Challenges

1. Competition from other Diagnostic Tests:

Syndromic testing contends with other diagnostic tests such as molecular diagnostics and serological diagnostics. These tests may provide more accurate information about the underlying cause of syndromes. Molecular diagnostics can pinpoint the specific pathogen causing the syndrome, while serological diagnostics can detect the presence of antibodies to the pathogen. These insights can guide diagnoses and treatment decisions. Healthcare providers may be accustomed to employing traditional diagnostic methods they are already familiar with, potentially leading to reluctance in adopting newer syndromic testing approaches. Diagnostic methods that have a long-standing history and established reliability may hold favor with healthcare professionals, making it challenging for syndromic testing to gain acceptance.

2. Quality Control and Standardization:

Quality control and standardization pose significant challenges in the global acute care syndromic testing market. Ensuring consistent and accurate results across different syndromic testing platforms and assays is essential for the reliability and reproducibility of diagnostic outcomes. Syndromic testing platforms may employ diverse technologies, chemistries, and reagents, which can lead to variability in assay performance. Variances in sensitivity, specificity, and limit of detection can impact result accuracy and reliability. Syndromic testing may be conducted in various laboratory settings, including clinical laboratories, hospitals, and point-of-care facilities. Inter-laboratory variability in testing procedures, equipment, and personnel expertise can affect result consistency. Syndromic testing assays targeting multiple pathogens simultaneously need to minimize cross-reactivity or interference between different targets. Cross-reactivity can yield false-positive or false-negative results.

3. Integration with Healthcare Systems:

Integrating syndromic testing technologies into existing healthcare systems and workflows is a significant challenge in the global acute care syndromic testing market. Seamless integration is crucial to maximize the benefits and widespread adoption of these technologies. Syndromic testing platforms need to be compatible with existing healthcare information systems, electronic health records (EHRs), and laboratory information management systems (LIMS). Ensuring smooth data exchange and interoperability can be technically complex. Syndromic testing generates substantial data that requires secure management, storage, and access by relevant healthcare professionals. Establishing robust data management and connectivity solutions is essential. Designing user-friendly interfaces that enable healthcare providers to easily access and interpret syndromic testing results within their existing workflow presents its own challenges. The design of user interfaces must prioritize usability and efficiency. Healthcare personnel, including clinicians, laboratory technicians, and IT staff, require training to effectively use and integrate syndromic testing technologies. Training programs must be comprehensive and ongoing. Introducing new technologies often necessitates changes to established clinical and laboratory workflows. Over coming resistance to change and ensuring a smooth transition are crucial for successful integration.

Key Market Trends

1. Rise of Point-of-Care Testing (POCT):

The rise of Point-of-Care Testing (POCT) emerges as a significant trend in the global Acute Care Syndromic Testing Market. Point-of-Care Testing pertains to diagnostic testing conducted at or near the patient's location, delivering rapid results that guide immediate clinical decision-making. POCT empowers healthcare providers to swiftly diagnose and initiate treatment plans, particularly in acute care settings where time sensitivity is paramount. Acute care syndromic testing, when adapted for POCT platforms, facilitates the prompt identification of pathogens responsible for acute symptoms, resulting in more timely and suitable interventions. Syndromic testing at the point of care eliminates the need to send samples to centralized laboratories, thereby reducing turnaround times for results. This rapidity is crucial in managing acute conditions and outbreaks, where swift decisions are essential. Point-of-care syndromic testing enables healthcare providers to make well-informed decisions at the bedside. Immediate results guide isolation measures, treatment choices, and patient management strategies, collectively enhancing overall care. During situations like infectious disease outbreaks, POCT-based acute care syndromic testing contributes to rapid containment by swiftly identifying cases and implementing appropriate control measures to forestall further spread. POCT optimizes resource allocation by negating the need for unnecessary transfers, repeat tests, and prolonged hospital stays. This efficiency is particularly pertinent in acute care scenarios marked by resource constraints. In the face of events like large gatherings or disaster responses, point-of-care syndromic testing can offer rapid screening for infectious diseases, aiding in swift identification and management of potential outbreaks. POCT can be especially advantageous in remote or underserved regions with limited access to central laboratories. Acute care syndromic testing at the point of care bridges diagnostic gaps, enhancing real-time disease surveillance, early detection of emerging pathogens, and timely public health responses.

Segmental Insights

Disease Type Insights

In 2022, the Respiratory Diseases Segment dominated the Acute Care Syndromic Testing Market and is projected to continue its expansion in the upcoming years. Respiratory diseases are among the leading global causes of death. According to the World Health Organization (WHO), respiratory diseases accounted for an estimated 4.1 million deaths in 2019. Respiratory diseases often manifest rapidly, making diagnosis and treatment challenging. Syndromic testing plays a crucial role in identifying the root cause of these diseases and initiating treatment promptly. Given that respiratory diseases often share common symptoms such as cough, fever, and shortness of breath, acute care syndromic testing proves instrumental in distinguishing between various respiratory pathogens and guiding appropriate treatment strategies. The significance of respiratory diseases in terms of public health impact, rapid transmission, and widespread consequences underscores the importance of effective outbreak management and containment through acute care syndromic testing. This segment is anticipated to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Target Insights

In 2022, the Bacteria Segment took precedence in the Acute Care Syndromic Testing Market and is forecasted to maintain its growth momentum in the years ahead. Bacteria are simple cells containing genetic information in a singular loop, and they can cause a range of infections affecting both humans and animals. Bacterial infections can manifest in various body parts, including the skin, brain, lungs, blood, and others. Bacterial infections often progress rapidly, posing challenges for diagnosis and treatment. Acute care syndromic testing plays a pivotal role in identifying the underlying cause of bacterial infections, facilitating early intervention. Given that bacterial infections can be contagious, prompt diagnosis becomes essential to prevent disease transmission. With its rapid results, syndromic testing proves effective in enhancing patient outcomes.

Sample Insight

In 2022, the Swabs Segment dominated the Acute Care Syndromic Testing Market and is projected to sustain its growth trajectory in the future. Nasopharyngeal swabs are particularly efficient in collecting samples from the upper respiratory tract, where various respiratory pathogens, including viruses like influenza and coronaviruses, are commonly found. Nasopharyngeal swabs provide direct access to the nasopharynx, often the initial site of infection for many respiratory viruses. This proximity enhances the sensitivity of pathogen detection.

End-User Insight

In 2022, the Hospital Segment held a prominent position in the Acute Care Syndromic Testing Market and is expected to continue expanding. Hospitals constitute primary settings for managing acute medical conditions, emergencies, and outbreaks. Syndromic testing proves particularly indispensable in these environments for promptly diagnosing and managing patients with urgent healthcare needs. Hospitals accommodate a diverse patient population and often handle high patient volumes, making them pivotal for syndromic testing. Rapidly identifying a wide array of pathogens is critical for patient care and infection control. Hospital emergency departments encounter a significant influx of acute cases, and syndromic testing streamlines triage and decision-making in such situations, enabling timely interventions.

Regional Insights

North America has established itself as a frontrunner in the Global Acute Care Syndromic Testing Market. The United States and Canada, in particular, possess advanced and well-developed healthcare infrastructure that fosters the swift adoption and integration of innovative diagnostic technologies, including acute care syndromic testing. The region is a hub for technological innovation and healthcare research, driving the development of cutting-edge syndromic testing platforms and solutions.

Please feel free to reach out for further information or additional insights.

Key Market Players

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocartis NV
• bioMerieux SA (BioFire Diagnostics)
• Danaher Corporation (Cepheid, Inc.)
• DiaSorin S.p.A (Luminex Corporation)
• Eurofins Scientific (Eurofins Viracor)
• Hologic Inc.
• Laboratory Corporation of America Holdings.
• QIAGEN N.V.
• QuantuMDx Group Ltd

Report Scope:

In this report, the Global Acute Care Syndromic Testing Markets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Care Syndromic Testing Market, By Disease Type:

• Respiratory Diseases
• Gastrointestinal Diseases
• Genitourinary Diseases
• Tropical Diseases
• Others

Acute Care Syndromic Testing Market, By Target:

• Bacteria
• Fungi
• Viruses
• Parasites

Acute Care Syndromic Testing Market, By Sample Type:

• Blood
• Urine
• Biofluids
• Stool
• Swabs
• Others

Acute Care Syndromic Testing Market, By End User:

• Hospitals
• Clinical & Diagnostics Laboratories
• Research & Academic Institutions
• Others

Global Acute Care Syndromic Testing Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Acute Care Syndromic Testing Market.

Available Customizations:

• Global Acute Care Syndromic Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Care Syndromic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Others)
  • 5.2.2. By Target (Bacteria, Viruses, Fungi, Parasites)
  • 5.2.3. By Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others)
  • 5.2.4. By End User (Hospitals, Clinical & Diagnostics Laboratories, Research & Academic Institutions, Others)
  • 5.2.5. By Company (2022)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Acute Care Syndromic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Target
  • 6.2.3. By Sample Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Care Syndromic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Target
      • 6.3.1.2.3. By Sample Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico Acute Care Syndromic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Target
      • 6.3.2.2.3. By Sample Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada Acute Care Syndromic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Target
      • 6.3.3.2.3. By Sample Type
      • 6.3.3.2.4. By End User

7. Europe Acute Care Syndromic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Target
  • 7.2.3. By Sample Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Acute Care Syndromic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Target
      • 7.3.1.2.3. By Sample Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Acute Care Syndromic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Target
      • 7.3.2.2.3. By Sample Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Acute Care Syndromic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Target
      • 7.3.3.2.3. By Sample Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Acute Care Syndromic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Target
      • 7.3.4.2.3. By Sample Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Acute Care Syndromic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Target
      • 7.3.5.2.3. By Sample Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Acute Care Syndromic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Target
  • 8.2.3. By Sample Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Acute Care Syndromic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Target
      • 8.3.1.2.3. By Sample Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Acute Care Syndromic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Target
      • 8.3.2.2.3. By Sample Type
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea Acute Care Syndromic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Target
      • 8.3.3.2.3. By Sample Type
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan Acute Care Syndromic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Target
      • 8.3.4.2.3. By Sample Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Acute Care Syndromic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Target
      • 8.3.5.2.3. By Sample Type
      • 8.3.5.2.4. By End User

9. South America Acute Care Syndromic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Target
  • 9.2.3. By Sample Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Acute Care Syndromic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Target
      • 9.3.1.2.3. By Sample Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Acute Care Syndromic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Target
      • 9.3.2.2.3. By Sample Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Acute Care Syndromic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Target
      • 9.3.3.2.3. By Sample Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Acute Care Syndromic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Target
  • 10.2.3. By Sample Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Acute Care Syndromic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Target
      • 10.3.1.2.3. By Sample Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Acute Care Syndromic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Target
      • 10.3.2.2.3. By Sample Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Acute Care Syndromic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Target

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Abbott Laboratories
  • 15.6.2. Becton, Dickinson and Company
  • 15.6.3. Biocartis NV
  • 15.6.4. bioMerieux SA (BioFire Diagnostics)
  • 15.6.5. Danaher Corporation (Cepheid, Inc.)
  • 15.6.6. DiaSorin S.p.A (Luminex Corporation)
  • 15.6.7. Eurofins Scientific (Eurofins Viracor)
  • 15.6.8. Karius
  • 15.6.9. Laboratory Corporation of America Holdings.
  • 15.6.10. QIAGEN N.V.
  • 15.6.11. QuantuMDx Group Ltd.

16. Strategic Recommendations